ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2959

Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout

Tony R. Merriman1, Marilyn E. Merriman1, Ruth Topless1, Sara Altaf2, Grant Montgomery3, Christopher Franklin4, Gregory T. Jones5, Andre M. van Rij2, Douglas HN White6, Lisa K. Stamp7, Nicola Dalbeth8 and Amanda Phipps-Green1, 1Department of Biochemistry, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Queensland Institute of Medical Research, Brisbane, Australia, 4University of Auckland, Auckland, New Zealand, 5Surgery, University of Otago, Dunedin, New Zealand, 6Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7University of Otago, Christchurch, New Zealand, 8Department of Medicine, University of Auckland, Auckland, New Zealand

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: genetics, Gout and uric acid

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Metabolic and Crystal Arthropathies II: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Ten are established, with a further 18 of weaker effect more recently detected. SLC2A9, ABCG2, SLC17A1 and GCKR, with stronger effect sizes, have been consistently associated with gout. Evidence for association with gout at the other 24 loci is absent, equivocal or not replicated, with one explanation likely to be non-clinical ascertainment of gout. Our aim was to test the loci with prevalent gout meeting the ACR gout classification criteria in Aotearoa New Zealand (NZ) European and Polynesian case-control sample sets.

Methods: 648 NZ European cases and 1550 controls, and 888 Polynesian (Māori and Pacific) cases and 1095 controls were genotyped. Association with gout was tested by logistic regression adjusting for age and sex, and ancestry estimate for Polynesians. Power was adequate (>0.7) to detect effects of OR>1.3.

Results: We focused on the 24 loci without consistent evidence for association with gout. Association was detected at seven loci in Europeans, one of which was the first report of association with gout (IGFR1) (Figure). In combined Polynesians association with gout was detected at three loci (SLC22A12, SFMBT1, VEGFA). Meta-analysis of Europeans and Polynesians revealed association at nine loci, two which had not previously been associated with gout (PDZK1 and MAF). In participants with higher Polynesian ancestry, there was association in an opposing direction to Europeans at PRKAG2 and HLF (Figure). In Europeans there was obvious inconsistency of gout association at four loci (GCKR, INHBC, SLC22A11, SLC16A9) that display very similar effects on urate levels.

Conclusion: We provide the first evidence for association with gout at four (IGRF1, PDZK1, MAF, HLF) serum urate loci not previously associated with gout. Understanding reasons for lack of correlation between urate and gout effect sizes will be important in understanding the etiology of urate control and risk of gout.

Reference: Kottgen et al. Nat Genet. 2013;45:145-54.

Figure Adjusted odds ratio of association of 28 serum loci with gout in NZ Europeans (yellow) and people with higher Polynesian ancestry (blue). Serum urate effect sizes taken from Kottgen et al. are shown (green triangles). * P ² 0.05, ** P ² 0.01, *** P ² 0.001, **** P ² 0.0001.


Disclosure:

T. R. Merriman,
None;

M. E. Merriman,
None;

R. Topless,
None;

S. Altaf,
None;

G. Montgomery,
None;

C. Franklin,
None;

G. T. Jones,
None;

A. M. van Rij,
None;

D. H. White,
None;

L. K. Stamp,
None;

N. Dalbeth,

Ardea,

5,

AstraZeneca,

5,

Takeda,

5,

Metabolex,

5,

Menarini,

8,

Savient,

8,

Novartis Pharmaceutical Corporation,

8,

Fonterra,

2,

Novartis Pharmaceutical Corporation,

2,

Ardea,

2,

Fonterra,

9;

A. Phipps-Green,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/twenty-eight-loci-that-influence-serum-urate-levels-analysis-of-association-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.